Johnson & Johnson’s experimental drug to treat two autoimmune diseases helped relieve symptoms when tested on adult patients in mid- and late-stage studies, the company said. J&J said the drug nipocalimumab significantly reduced symptoms of generalised myasthenia gravis in the late-stage trial and helped reduce the severity of Sjögren’s disease in the interim study.